TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Researchers report that following up brexucabtagene autoleucel (brexu-cel) treatment with tyrosine kinase inhibitor (TKI)-based maintenance therapy produces a survival benefit in adults with...

New evidence upholds bendamustine as a viable alternative to fludarabine in lymphodepleting (LD) chemotherapy ahead of chimeric antigen receptor (CAR) T-cell treatment.

Recent study findings may offer clues into what kind of scenarios support or undermine chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed/refractory B-cell acute...

Injection of chimeric antigen receptor (CAR) T cells into the brain effectively treats glioblastoma multiforme (GBM), a particularly aggressive type of brain tumor, but researchers say the effect...

Scientists report promising early results from a novel approach for preventing graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT).

Single-cell RNA sequencing of 40 idecabtagene vicleucel (ide-cel) products sheds light on the role that NF-κB signaling plays in the durability of response to chimeric antigen receptor (CAR)...